Catalog No.
DHC06704
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-kappa
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
Granulocyte-macrophage colony-stimulating factor, Sargramostim, GMCSF, CSF, Colony-stimulating factor, CSF2, GM-CSF, Molgramostin
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P04141
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
MORAb-022, CAS: 1648796-29-5
Clone ID
Gimsilumab
Note
For research use only. Not suitable for clinical or therapeutic use.
GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches., PMID:32576980
Pharmaco-Immunomodulatory Therapy in COVID-19., PMID:32696108
Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies., PMID:32719685
Repurposed Drugs, Molecular Vaccines, Immune-Modulators, and Nanotherapeutics to Treat and Prevent COVID-19 Associated with SARS-CoV-2, a Deadly Nanovector., PMID:33173808
Prone Positioning and Survival in Mechanically Ventilated Patients With Coronavirus Disease 2019-Related Respiratory Failure., PMID:33595960
Cardiovascular Disease and Severe Hypoxemia Are Associated With Higher Rates of Noninvasive Respiratory Support Failure in Coronavirus Disease 2019 Pneumonia., PMID:33655216
Variation in Initial U.S. Hospital Responses to the Coronavirus Disease 2019 Pandemic., PMID:33826584
Multisociety statement on coronavirus disease 2019 (COVID-19) vaccination as a condition of employment for healthcare personnel., PMID:34253266
Anti-Granulocyte-Macrophage Colony-Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial., PMID:35290169
Less Haste, More Speed, More Science: Lessons to be Learned from COVID-19 Studies., PMID:35442181
Erratum: Anti-Granulocyte-Macrophage Colony-Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial., PMID:36112778
Variation in Initial U.S. Hospital Responses to the Coronavirus Disease 2019 Pandemic, PMID: 33826584
Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies, PMID: 32719685
Repurposed Drugs, Molecular Vaccines, Immune-Modulators, and Nanotherapeutics to Treat and Prevent COVID-19 Associated with SARS-CoV-2, a Deadly Nanovector, PMID: 33173808
Prone Positioning and Survival in Mechanically Ventilated Patients With Coronavirus Disease 2019-Related Respiratory Failure, PMID: 33595960
Pharmaco-Immunomodulatory Therapy in COVID-19, PMID: 32696108
Multisociety statement on coronavirus disease 2019 (COVID-19) vaccination as a condition of employment for healthcare personnel, PMID: 34253266
GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches, PMID: 32576980
Cardiovascular Disease and Severe Hypoxemia Are Associated With Higher Rates of Noninvasive Respiratory Support Failure in Coronavirus Disease 2019 Pneumonia, PMID: 33655216
For research use only. Not for human or drug use.
